Brexucabtagene Autoleucel (KTE-X19)

BIOLOGICAL2 trials

Sponsors

Kite, A Gilead Company

Conditions

Relapse/Refractory Mantle Cell LymphomaRelapsed/Refractory B-Cell Non-Hodgkin LymphomaRelapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Phase 1

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

CompletedNCT02625480

Kite, A Gilead CompanyRelapsed/Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Start: 2016-02-01End: 2026-03-25Updated: 2026-04-09

Unknown Phase

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

Kite, A Gilead CompanyRelapse/Refractory Mantle Cell Lymphoma

Updated: 2021-10-14

Related Papers

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Haematologica2022-10-2037 citations

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Blood2020-11-045 citations

Primary mediastinal large B‐cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy

British Journal of Haematology2020-05-296 citations

Immunotherapies for Pediatric B-Cell Acute Lymphoblastic Leukemia Patients

Oncology Times2019-04-25

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood2016-12-0229 citations

Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)

Blood2016-12-0224 citations

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).

Journal of Clinical Oncology2016-05-207 citations

650. Development of a Manufacturing Process Using Monte Carlo Simulations to Support KTE-C19 (Anti-CD19 CAR T Cells) Studies in Leukemia

Molecular Therapy2016-05-01